Table 8.
Skin-related side effects of Slovak healthcare workers who received BNT162b2 and stratified by gender, February–March 2021 (n = 522).
| Variable | Outcome | Female (n = 402) | Male (n = 120) | Total (n = 522) | Sig. |
|---|---|---|---|---|---|
| Skin-related Side Effect Prevalence | Rash | 7 (1.7%) | 1 (0.8%) | 8 (1.5%) | 0.689 |
| Angioedema | 11 (2.7%) | 2 (1.7%) | 13 (2.5%) | 0.742 | |
| Intensity (0–3) | 0.04 ± 0.23 | 0.03 ± 0.20 | 0.04 ± 0.22 | 0.228 | |
| Total (n) | 16 (4%) | 2 (1.7%) | 18 (3.4%) | 0.390 | |
| Skin-related Side Effect Location (n = 18) |
Face | 5 (31.3%) | 0 (0%) | 5 (27.8%) | 1.000 |
| Upper Limb | 9 (56.3%) | 2 (100%) | 11 (61.1%) | 0.497 | |
| Lower Limb | 2 (12.5%) | 1 (50%) | 3 (16.7%) | 0.314 | |
| Torso | 6 (37.5%) | 1 (50%) | 7 (38.9%) | 1.000 | |
| Back | 2 (12.5%) | 2 (100%) | 4 (22.2%) | 0.039 |
Fisher’s exact test and Mann–Whitney test (U) were used with a significance level (Sig.) of < 0.05.